Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with Type 1 diabetes mellitus who fast during Ramadan: A systematic review and meta-analysis

Hoda Gad, Hamad Al-Muhannadi, Paul Mussleman, Rayaz Malik

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Background: The benefits and risks of continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI) in patients with Type 1 diabetes mellitus (T1DM) who fast during Ramadan are not known. Methods: Systematic review and meta-analysis of observational studies conducted in PubMed, Embase (Ovid), and the Cochrane Library. Quality of included studies was assessed using the ROBINS-I tool for risk of bias assessment and analyses were performed using RevMan version 5.1. Results: From 709 records, 306 full text studies were assessed. After exclusions, the final analysis included a total of 9 studies. Heterogeneity for outcomes was I 2 = 0%. There was no significant difference for the change in glycemic control (HbA 1c ) between CSII and MDI (P > 0.05). There was no change in weight or the lipid profile in patients with T1DM on MDI during Ramadan. There were insufficient data to assess the impact on glucose profiles and the incidence of hypoglycemia or diabetic ketoacidosis (DKA) in patients on CSII or MDI during Ramadan. Conclusions: Studies assessing the effect of CSII or MDI in patients with T1DM who fast during Ramadan are limited to observational studies and show no difference in the change in Hb A1 c, weight or lipids during Ramadan.

Original languageEnglish
JournalDiabetes Research and Clinical Practice
DOIs
Publication statusPublished - 1 Jan 2019

Fingerprint

Subcutaneous Infusions
Type 1 Diabetes Mellitus
Meta-Analysis
Insulin
Injections
Observational Studies
Lipids
Weights and Measures
Diabetic Ketoacidosis
Glycosylated Hemoglobin A
Hypoglycemia
PubMed
Libraries
Glucose
Incidence

Keywords

  • CSII
  • MDI
  • Metabolic control
  • Ramadan fasting
  • T1DM

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

@article{bb9b62fc7d8244089966bf6aafc4ff4c,
title = "Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with Type 1 diabetes mellitus who fast during Ramadan: A systematic review and meta-analysis",
abstract = "Background: The benefits and risks of continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI) in patients with Type 1 diabetes mellitus (T1DM) who fast during Ramadan are not known. Methods: Systematic review and meta-analysis of observational studies conducted in PubMed, Embase (Ovid), and the Cochrane Library. Quality of included studies was assessed using the ROBINS-I tool for risk of bias assessment and analyses were performed using RevMan version 5.1. Results: From 709 records, 306 full text studies were assessed. After exclusions, the final analysis included a total of 9 studies. Heterogeneity for outcomes was I 2 = 0{\%}. There was no significant difference for the change in glycemic control (HbA 1c ) between CSII and MDI (P > 0.05). There was no change in weight or the lipid profile in patients with T1DM on MDI during Ramadan. There were insufficient data to assess the impact on glucose profiles and the incidence of hypoglycemia or diabetic ketoacidosis (DKA) in patients on CSII or MDI during Ramadan. Conclusions: Studies assessing the effect of CSII or MDI in patients with T1DM who fast during Ramadan are limited to observational studies and show no difference in the change in Hb A1 c, weight or lipids during Ramadan.",
keywords = "CSII, MDI, Metabolic control, Ramadan fasting, T1DM",
author = "Hoda Gad and Hamad Al-Muhannadi and Paul Mussleman and Rayaz Malik",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.diabres.2019.02.019",
language = "English",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with Type 1 diabetes mellitus who fast during Ramadan

T2 - A systematic review and meta-analysis

AU - Gad, Hoda

AU - Al-Muhannadi, Hamad

AU - Mussleman, Paul

AU - Malik, Rayaz

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: The benefits and risks of continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI) in patients with Type 1 diabetes mellitus (T1DM) who fast during Ramadan are not known. Methods: Systematic review and meta-analysis of observational studies conducted in PubMed, Embase (Ovid), and the Cochrane Library. Quality of included studies was assessed using the ROBINS-I tool for risk of bias assessment and analyses were performed using RevMan version 5.1. Results: From 709 records, 306 full text studies were assessed. After exclusions, the final analysis included a total of 9 studies. Heterogeneity for outcomes was I 2 = 0%. There was no significant difference for the change in glycemic control (HbA 1c ) between CSII and MDI (P > 0.05). There was no change in weight or the lipid profile in patients with T1DM on MDI during Ramadan. There were insufficient data to assess the impact on glucose profiles and the incidence of hypoglycemia or diabetic ketoacidosis (DKA) in patients on CSII or MDI during Ramadan. Conclusions: Studies assessing the effect of CSII or MDI in patients with T1DM who fast during Ramadan are limited to observational studies and show no difference in the change in Hb A1 c, weight or lipids during Ramadan.

AB - Background: The benefits and risks of continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI) in patients with Type 1 diabetes mellitus (T1DM) who fast during Ramadan are not known. Methods: Systematic review and meta-analysis of observational studies conducted in PubMed, Embase (Ovid), and the Cochrane Library. Quality of included studies was assessed using the ROBINS-I tool for risk of bias assessment and analyses were performed using RevMan version 5.1. Results: From 709 records, 306 full text studies were assessed. After exclusions, the final analysis included a total of 9 studies. Heterogeneity for outcomes was I 2 = 0%. There was no significant difference for the change in glycemic control (HbA 1c ) between CSII and MDI (P > 0.05). There was no change in weight or the lipid profile in patients with T1DM on MDI during Ramadan. There were insufficient data to assess the impact on glucose profiles and the incidence of hypoglycemia or diabetic ketoacidosis (DKA) in patients on CSII or MDI during Ramadan. Conclusions: Studies assessing the effect of CSII or MDI in patients with T1DM who fast during Ramadan are limited to observational studies and show no difference in the change in Hb A1 c, weight or lipids during Ramadan.

KW - CSII

KW - MDI

KW - Metabolic control

KW - Ramadan fasting

KW - T1DM

UR - http://www.scopus.com/inward/record.url?scp=85063945393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063945393&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2019.02.019

DO - 10.1016/j.diabres.2019.02.019

M3 - Review article

C2 - 30825561

AN - SCOPUS:85063945393

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

ER -